카나비노이드 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Cannabinoids Market size is expected to reach USD 363.88 Billion in 2034 from USD 57.85 Billion (2025) growing at a CAGR of 22.67% during 2026-2034.

The global cannabinoids market has expanded rapidly as legal reform, clinical research, and consumer interest in CBD and other cannabinoid products converge. Medical legalization in parts of North America and Europe opened pharmaceutical and wellness channels, while broad consumer adoption of topicals, nutraceuticals, and functional foods created diverse revenue streams. Investment across cultivation, extraction, and formulation technologies increased industrial capacity and product variety, accelerating market growth and commercial visibility.

Key drivers include increasing clinical and preclinical evidence for cannabinoids' potential in pain management, epilepsy, and other indications, plus regulatory loosening in several jurisdictions that create commercial opportunities. Advancements in extraction, purification, and consistent formulation-along with delivery innovations such as nanoemulsions and transdermal systems-improve bioavailability and consumer confidence. Vertical integration by larger players and strategic M&A activity also professionalize supply chains and raise quality standards across the sector.

Future prospects are robust but regionally varied: pharmaceutical-grade cannabinoid therapeutics could capture high-value market segments if late-stage trials confirm efficacy, while consumer markets will mature with standardized dosing and clearer labeling. Expect consolidation as large firms pursue vertically integrated supply chains and as regulators emphasize quality control and traceability. Continued innovation in delivery platforms and clinical research will shape therapeutic adoption and long-term growth trajectories.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product Type

• Cannabidiol
• Tetrahydrocannabinol
• Cannabinol
• Others

By Application

• Medicinal Use (Chronic Pain, Neurological Disorders Management, Oncology, Others)
• Non-medical Use

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Stores

COMPANIES PROFILED

• Mylan NV Viatris Inc, Alkem Labs, GW Pharmaceuticals plc Jazz Pharmaceuticals, Tilray Inc, Aurora Cannabis Inc, Canopy Growth Corporation, The Cronos Group, Endoca, Cannoid LLC, Medical Marijuana Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CANNABINOIDS MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product Type
• 4.2. Cannabidiol Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Tetrahydrocannabinol Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Cannabinol Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CANNABINOIDS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Medicinal Use (Chronic Pain, Neurological Disorders Management, Oncology, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Non-medical Use Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CANNABINOIDS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Stores Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CANNABINOIDS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product Type
  • 7.2.2 By Application
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product Type
  • 7.3.2 By Application
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product Type
  • 7.4.2 By Application
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product Type
  • 7.5.2 By Application
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product Type
  • 7.6.2 By Application
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CANNABINOIDS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Mylan N.V. (Viatris Inc.)
  • 9.2.2 Alkem Labs
  • 9.2.3 GW Pharmaceuticals Plc (Jazz Pharmaceuticals)
  • 9.2.4 Tilray Inc
  • 9.2.5 Aurora Cannabis Inc
  • 9.2.6 Canopy Growth Corporation
  • 9.2.7 The Cronos Group
  • 9.2.8 Endoca
  • 9.2.9 Cannoid LLC
  • 9.2.10 Medical Marijuana Inc